Daily Edition · Page 1

THE DAILY INDEX

Technology, AI, software, security, crypto and business

Across today’s newsletters

Today’s Index

MUSK TESTIFIES HE'S SUING OPENAI TO STOP ALTMAN'S ‘LOOTING'

Elon Musk says that OpenAI's pivot from a charity to a for-profit business is wrong and sets a concerning precedent for other philanthropic efforts. He is suing OpenAI and its co-founders, seeking the unwinding of the for-profit restructuring of OpenAI. Musk says he felt that OpenAI's founders took advantage of his money, reputation, and guidance to get the startup off the ground, only to abandon its public-focused principles and capitalize on the project for their own benefit. OpenAI's attorneys say that the lawsuit is primarily an attempt to undermine a top competitor to Musk's own AI company.

AN INTERVIEW WITH OPENAI CEO SAM ALTMAN AND AWS CEO MATT GARMAN ABOUT BEDROCK MANAGED AGENTS

OpenAI CEO Sam Altman and AWS CEO Matt Garman recently sat down for an interview where they talked about Bedrock Managed Agents powered by OpenAI and how that would fit in with OpenAI's deal with Microsoft giving Azure exclusive access to OpenAI models. Microsoft and OpenAI have since amended their agreement to allow OpenAI to serve its products on other cloud providers. Azure's exclusivity was actively damaging Microsoft's investment in OpenAI, so Microsoft needed to do something, even if it meant diminishing Azure's differentiation. OpenAI also released Microsoft from the AGI clause, which means the agreement between the two companies will run until 2032 even if OpenAI achieves AGI.

SCROLL-DRIVEN ANIMATIONS

The new CSS `animation-timeline` API allows devs to create scroll-driven animations natively in CSS, moving away from JavaScript solutions. The API extends existing CSS keyframe animations by mapping their progress to an element's visibility within the viewport or the document's overall scroll position. These animations can be finely controlled using various timing functions, precise animation ranges like `entry` or `exit`, and even link animations across different elements.

SNAPCHAT BRINGS AI-POWERED CONVERSATIONAL ADVERTISING TO ITS APP

Snapchat is rolling out “AI Sponsored Snaps,” a new ad format that lets users chat directly with brands' AI agents inside the app's Chat tab, allowing them to ask questions, get product recommendations, and interact with ads conversationally. The company says the feature builds on the success of Sponsored Snaps, which already drive higher conversions at lower costs, and reflects Snap's belief that chat-based interactions are becoming a major part of digital advertising as users increasingly engage with messaging and AI-powered conversations inside the app.

2026: THE YEAR OF CHURN

"Does it integrate with Salesforce?" was the question buyers asked for a decade. Now, they want to know if agents can drive your product, if your APIs are clean, and if there's an MCP connector. Buyers asking those questions are buyers running the math on whether to keep you. The math gets worse when a vendor they already pay adds a 60% version of what you do, because AI fills enough of the rest that cutting your $80K contract stops feeling like a tradeoff. Annual deals have hidden how often this is already happening.

CURIOUS CASES OF FINANCIAL ENGINEERING IN BIOTECH

Finance doesn't really make drug development easier. However, it does make failure more survivable. Financialization is just the process of making implicit economic relationships explicit and tradable. Having more liquid markets for biotech risk is almost certainly better than having fewer. The industry being willing to fund biology that's expensive and likely to fail could result in more discoveries that change the world.

ANTIBIOTICS ARE AN ECONOMIC FAILURE

The discovery of antibiotics enabled many of our modern medical procedures, including many routine surgeries and immunosuppressant treatments such as chemotherapy. Antibiotic resistance is considered to be one of the greatest public health threats to humanity. If a new antibiotic entered the market, it would either be used as a last line of defense, which means few doses would be sold, or it would be widely used until resistance developed again, after which sales would drop. Antibiotics are only used for a few days, so there's little profit potential. These factors mean there's less money in developing and selling antibiotics compared to drugs for chronic diseases.

TLDR IndexPage 1